ADC Therapeutics S.A.
ADCTNYSEHealthcare● Active
$0.98
$-0.05(-5.08%)
Market Cap$124354641
P/E Ratio—
52W High$4.98
52W Low$0.7796
ADC Therapeutics S.A. (ADCT) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
ADCT · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 4, 2026EPS Actual
-$0.21
Est. -$0.19 · -10.5%
Revenue
$0.02B
Est. $0.02B · +4.3%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 4, 2026
After Market Close
▼ Miss EPS▲ Beat Revenue
ADCT reports quarterly as a NYSE-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Rev. $0.58B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
Rev. Est.$0.58B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 11, 2026 | -$0.19 | — | — | — | $0.02B | — |
| ▼ Q2 FY2026 | May 4, 2026 | -$0.19 | -$0.21 | -10.5% | $0.02B | $0.02B | +4.3% |
| ▲ Q1 FY2026 | Mar 10, 2026 | -$0.32 | -$0.04 | +87.5% | $0.02B | $0.02B | +3.4% |
| ▲ Q4 FY2025 | Nov 10, 2025 | -$0.40 | -$0.30 | +25.0% | $0.02B | $0.02B | -23.8% |
| ▼ Q3 FY2025 | Aug 12, 2025 | -$0.36 | -$0.50 | -38.9% | $0.02B | $0.02B | +3.5% |
| ▲ Q2 FY2025 | May 14, 2025 | -$0.38 | -$0.36 | +5.3% | $0.02B | $0.02B | +31.3% |
| ▲ Q1 FY2025 | Mar 27, 2025 | -$0.35 | -$0.29 | +17.1% | $0.02B | $0.02B | -11.0% |
| ▼ Q4 FY2024 | Nov 7, 2024 | -$0.36 | -$0.42 | -16.7% | $0.02B | $0.02B | -2.0% |
Q3 FY2026
Aug 11, 2026
EPS Actual
—
EPS Est.
-$0.19
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 4, 2026Miss
EPS Actual
-$0.21
EPS Est.
-$0.19
EPS Surpr.
-10.5%
Revenue
$0.02B
Q1 FY2026
Mar 10, 2026Beat
EPS Actual
-$0.04
EPS Est.
-$0.32
EPS Surpr.
+87.5%
Revenue
$0.02B
Q4 FY2025
Nov 10, 2025Beat
EPS Actual
-$0.30
EPS Est.
-$0.40
EPS Surpr.
+25.0%
Revenue
$0.02B
Q3 FY2025
Aug 12, 2025Miss
EPS Actual
-$0.50
EPS Est.
-$0.36
EPS Surpr.
-38.9%
Revenue
$0.02B
Q2 FY2025
May 14, 2025Beat
EPS Actual
-$0.36
EPS Est.
-$0.38
EPS Surpr.
+5.3%
Revenue
$0.02B
Q1 FY2025
Mar 27, 2025Beat
EPS Actual
-$0.29
EPS Est.
-$0.35
EPS Surpr.
+17.1%
Revenue
$0.02B
Q4 FY2024
Nov 7, 2024Miss
EPS Actual
-$0.42
EPS Est.
-$0.36
EPS Surpr.
-16.7%
Revenue
$0.02B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $-0.10 | $-0.09 | $-0.08 | 1 |
| Q3 FY2027 | $-0.16 | $-0.15 | $-0.13 | 1 |
| Q2 FY2027 | $-0.21 | $-0.19 | $-0.17 | 1 |
| Q1 FY2027 | $-0.20 | $-0.18 | $-0.16 | 1 |
| Q4 FY2026 | $-0.22 | $-0.20 | $-0.18 | 1 |
| Q3 FY2026 | $-0.24 | $-0.22 | $-0.19 | 3 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 2 |
| Q2 FY2027 | $0.0B | $0.0B | $0.0B | 2 |
| Q1 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 2 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 3 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q2 FY2026 | May 4, 2026 | -10.5% | $3.83 | $3.68 | -3.92% |
| ▲ Q1 FY2026 | Mar 10, 2026 | +87.5% | $4.23 | $4.80 | +13.48% |
| ▲ Q4 FY2025 | Nov 10, 2025 | +25.0% | $4.04 | $4.21 | +4.21% |
| ▼ Q3 FY2025 | Aug 12, 2025 | -38.9% | $2.68 | $2.94 | +9.70% |
| ▲ Q2 FY2025 | May 14, 2025 | +5.3% | $1.32 | $1.81 | +37.12% |
| ▲ Q1 FY2025 | Mar 27, 2025 | +17.1% | $1.58 | $1.52 | -3.80% |
| ▼ Q4 FY2024 | Nov 7, 2024 | -16.7% | $3.20 | $2.93 | -8.44% |
| ▲ Q3 FY2024 | Aug 6, 2024 | +13.6% | $2.87 | $2.92 | +1.74% |
Q2 FY2026-3.92%
Report Date
May 4, 2026
EPS Beat/Miss
-10.5%
Price Before
$3.83
Price After
$3.68
Q1 FY2026+13.48%
Report Date
Mar 10, 2026
EPS Beat/Miss
+87.5%
Price Before
$4.23
Price After
$4.80
Q4 FY2025+4.21%
Report Date
Nov 10, 2025
EPS Beat/Miss
+25.0%
Price Before
$4.04
Price After
$4.21
Q3 FY2025+9.70%
Report Date
Aug 12, 2025
EPS Beat/Miss
-38.9%
Price Before
$2.68
Price After
$2.94
Q2 FY2025+37.12%
Report Date
May 14, 2025
EPS Beat/Miss
+5.3%
Price Before
$1.32
Price After
$1.81
Q1 FY2025-3.80%
Report Date
Mar 27, 2025
EPS Beat/Miss
+17.1%
Price Before
$1.58
Price After
$1.52
Q4 FY2024-8.44%
Report Date
Nov 7, 2024
EPS Beat/Miss
-16.7%
Price Before
$3.20
Price After
$2.93
Q3 FY2024+1.74%
Report Date
Aug 6, 2024
EPS Beat/Miss
+13.6%
Price Before
$2.87
Price After
$2.92
Avg Beat Reaction+10.55%
Avg Miss Reaction-0.89%
Beat Rate5 / 8 quarters
Largest Move+37.12% (Q2 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: ADCT ends December
ADC Therapeutics S.A. (ADCT) most recently reported earnings on May 4, 2026 for Q2 FY2026, posting EPS of $-0.21 — missing the analyst consensus of $-0.19 by -10.5%. The next ADCT earnings date is expected around September 1, 2026.
Each quarter, investors track ADCT earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. ADCT revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
ADCT's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
ADCT earnings · 5 questionsADC Therapeutics S.A.'s next earnings report is expected around September 1, 2026. ADCT typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; ADCT historically reports after market close (AMC).
ADCT earnings datewhen is ADCT earningsADCT next earnings datewhen does ADCT report earningsADCT earnings calendar
▸ Source: FMP · ADC Therapeutics S.A. SEC filings · US GAAP · ADC Therapeutics S.A. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026